Glucuronide prodrugs of tofacitinib
US10472366B2 · kind B2 · utility
0Cited by
2References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 7, 2018 |
| Grant date | Nov 12, 2019 |
| Priority date | — |
| Expiry date | Mar 7, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H17/02
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.